<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867021</url>
  </required_header>
  <id_info>
    <org_study_id>V71_22</org_study_id>
    <nct_id>NCT01867021</nct_id>
  </id_info>
  <brief_title>Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above</brief_title>
  <official_title>A Multi-Center, Phase IV, Randomized, Controlled, Observer Blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Trivalent Subunit Inactivated Influenza Vaccine in Healthy Subjects Aged 50 Years and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate non-inferiority of the post-vaccination (Day 22) Hemagglutination inhibition (HI)
      Geometric Mean Titers (GMTs) of trivalent, inactivated, subunit influenza vaccine (TIV) over
      the corresponding GMTs of the comparator vaccine for all three strains, in healthy adults
      aged 50 years and above.

      Demonstrate non-inferiority of the percentages of subjects achieving seroconversion in
      antibody titers at Day 22 in the TIV group over the corresponding percentages of subjects in
      the comparator group for all three strains, in healthy adults aged 50 years and above.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV Group and TIVf Group for All Three Strains, in Healthy Adults Aged ≥50 Years</measure>
    <time_frame>Day 22</time_frame>
    <description>Non-inferiority of Postvaccination Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV (Trivalent Subunit Inactivated Influenza Vaccine) Group Over the Corresponding TIVf Group for All Three Strains, three weeks after vaccination (day 22).
The upper limit of the two-sided 95% confidence interval (CI) on the ratio of GMTs (GMT TIVf/GMT TIV) should not exceed the non-inferiority margin of 1.5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects Achieving Seroconversion (SC) in Antibody Titers in the TIV Group Compared With the Corresponding Percentages of Subjects in the TIVf Group for All Three Strains At Day 22, in Healthy Adults Aged ≥50 Years</measure>
    <time_frame>Day 22</time_frame>
    <description>Non-Inferiority was measured as the percentages of subjects who achieved seroconversion in HI titers three weeks (day 22) after vaccination of TIV compared with TIVf, against each of three vaccine strains.
Seroconversion is defined as a prevaccination titer &lt;10 and postvaccination HI ≥40 or as a prevaccination titer ≥10 and at minimum four-fold rise in postvaccination antibody titer.
The upper limit of the two-sided 95% CI on the difference between the seroconversion rates (Seroconversion TIVf - SeroconversionTIV) should not exceed 10%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Percentages of Subjects Who Achieved HI Seroconversion and HI Titer ≥1:40 Against Each of Three Strains After One Vaccination of TIV and TIVf Vaccine</measure>
    <time_frame>Day 22</time_frame>
    <description>Percentage of subjects achieving HI seroconversion against each of three vaccine strains was measured three weeks after vaccination of TIV and TIVf vaccine (day 22).
Percentage of subjects who achieved HI titer ≥1:40 against each of three vaccine strains was measured three weeks after one vaccination of TIV and TIVf vaccine.
According to Center for Biologics Evaluation and Research recommendations (CBER 2007), the criterion for seroconversion is considered met if the lower limit of the two-sided 95% CI for the percentage of subjects with HI seroconversion is ≥40% (&lt;65 years) or ≥30% (≥65 years).
As per the CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects who achieved HI titer ≥ 1:40 should be ≥70% (&lt;65 years) or ≥60% (≥65 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio of Subjects Against Each of Three Strains After One Vaccination of TIV and TIVf Vaccine</measure>
    <time_frame>Day 22</time_frame>
    <description>Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs against each of three vaccine strains, three weeks after vaccination of TIV and TIVf vaccine (day 22).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Solicited Local and Systemic Adverse Events After One Vaccination of TIV and TIVf</measure>
    <time_frame>Day 1 to 7 postvaccination</time_frame>
    <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after vaccination of TIV and control.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2902</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Agriflu</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 0.5 mL dose of Investigational vaccine TIV (Agriflu) at visit 1, administered intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluvirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 0.5 mL dose of control vaccine TIVf (Fluvirin) at visit 1, administered intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluvirin(TIVf)</intervention_name>
    <arm_group_label>Fluvirin</arm_group_label>
    <other_name>Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Agriflu (TIV)</intervention_name>
    <arm_group_label>Agriflu</arm_group_label>
    <other_name>Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 50 years and above, mentally competent, willing and able to
             give written informed consent prior to study entry and after the nature of the study
             has been explained according to local regulatory requirements.

          -  Individuals able to comply with all the study requirements.

          -  Individuals in good health as determined by the outcome of medical history, physical
             examination and clinical judgment of the investigator.

        Exclusion Criteria:

          -  Individuals with behavioral or cognitive impairment or psychiatric disease that, in
             the opinion of the investigator, may interfere with the subject's ability to
             participate in the study.

          -  Individuals with any progressive or severe neurologic disorder, seizure disorder or
             Guillain-Barré syndrome.

          -  Individuals who are not able to comprehend and to follow all required study procedures
             for the whole period of the study.

          -  Individuals who have received any seasonal or pandemic influenza vaccine or have had a
             laboratory confirmed seasonal or pandemic influenza disease within the past 6 months.

          -  Individuals with history or any illness that, in the opinion of the investigator,
             might interfere with the results of the study or pose additional risk to the subjects
             due to participation in the study.

          -  Individuals with positive HIV test result, with history of an autoimmune disorder or
             any other known or suspected impairment /alteration of the immune system, or under
             immunosuppressive therapy within 6 months or use of any parenteral or oral
             corticosteroids within the previous 30 days.

          -  Individuals with a known bleeding diathesis, or any condition that may be associated
             with a prolonged bleeding time.

          -  Individuals with any serious chronic or progressive disease according to judgment of
             the investigator (neoplasm, insulin dependent diabetes, cardiac, renal or hepatic
             disease).

          -  Individuals who have any malignancy (excluding nonmelanotic skin cancer) or
             lymphoproliferative disorder.

          -  Individuals with history of any anaphylactic adverse event and/or serious allergic
             adverse event following a vaccination, a proven hypersensitivity to any component of
             the study vaccine (eg, to eggs or eggs product as well as ovalbumin, chicken protein,
             chicken feathers, influenza viral protein, kanamycin and neomycin sulphate) or latex
             allergy.

          -  Individuals participating in any clinical trial with another investigational product
             30 days prior to first study visit or intent to participate in another clinical study
             at any time during the conduct of this study.

          -  Receipt of nonstudy vaccines (with the exception of post-exposure vaccination in a
             medical emergency, eg, hepatitis, rabies, tetanus) within 3 weeks prior to Visit 1.

          -  Individuals who have ever received blood, blood products and/or plasma derivatives or
             any parenteral immunoglobulin preparation in the past 12 weeks.

          -  Individuals who have received antibiotics within 6 days before vaccination.

          -  Individuals with body temperature (axillary temperature) ≥38 degrees Celsius (≥ 100.4°
             F) within the last 3 days of intended study vaccination.

          -  BMI &gt; 35 kg/m2.

          -  Female who are pregnant or nursing (breastfeeding) mothers or females of childbearing
             potential do not plan to use acceptable birth control measures, for the whole duration
             of the study. Adequate contraception is defined as hormonal (eg, oral, injection,
             transdermal patch, implant, cervical ring), barrier (eg, condom with spermicide or
             diaphragm with spermicide), intrauterine device (IUD), or monogamous relationship with
             vasectomized partner who has been vasectomized for 6 months or more prior to the
             subject's study entry; Abstinence.

          -  Individuals who are part of study personnel or close family members conducting this
             study.

          -  Individuals with history of substance or alcohol abuse within the past 2 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 71 - Ordinace všeobecného lékaře</name>
      <address>
        <city>Kbel 163</city>
        <state>Benátky nad Jizerou</state>
        <zip>294 71</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 70 - Vaccination and Travel Medicine Centre</name>
      <address>
        <city>Poliklinika II., Bratri Stefanu 895</city>
        <state>Hradec Kralove</state>
        <zip>500 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 61 - Research Institute for Tropical Medicine DOH Compound</name>
      <address>
        <city>Filinvest Corporate City</city>
        <state>Alabang Muntinlupa City</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 60 - De La Salle Health Sciences Institute, Room 6210 and 6206 De La Salle Angelo King Medical Research Center</name>
      <address>
        <city>Congressional Road, Dasmarinas City</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 63 - Our Lady of Lourdes Hospital, 46 P. Sanchez Street, Sta.</name>
      <address>
        <city>Mesa</city>
        <state>Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 62 - Research Institute for Tropical Medicine DOH Compound, Filinvest Corporate City</name>
      <address>
        <city>Alabang</city>
        <state>Muntinlupa City</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33 - TREAD Research , Room 41, 8th Floor, Department of Cardiology, Tygerberg Hospital, Francie van Zijl Drive</name>
      <address>
        <city>Province of the Western Cape</city>
        <state>Cape Town</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43 - Allergy Diagnostic &amp; Clinical Research Unit, UCT Lung Institute, George Street</name>
      <address>
        <city>Province of the Western Cape</city>
        <state>Cape Town</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34 - Synopsis Research, Room 8, First floor, Fountain Centre, Belmont Road</name>
      <address>
        <city>Rondebosch</city>
        <state>Cape Town</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 41 - Tiervlei Trial Centre, Karl Bremer Hospital, c/o Mike Pienaar Boulevard &amp; Frans Conradie Avenue, Bellville</name>
      <address>
        <city>Western Cape</city>
        <state>Cape Town</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45 - 343 Randles Road</name>
      <address>
        <city>Sydenham</city>
        <state>Durban</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 44 - Dr B van der Berg and Associates, 162 Pretoria Road, Rynfield</name>
      <address>
        <city>Benoni</city>
        <state>Gauteng</state>
        <zip>1511</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31 - MD Search, 1 Paul Smit Street</name>
      <address>
        <city>Boksburg North</city>
        <state>Gauteng</state>
        <zip>1459</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32 - EMMED Research, Emmed Research, 641 5th Avenue</name>
      <address>
        <city>Eloffsdal</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35 - I Engelbrecht Research (Pty) Ltd, 174 Cradock Avenue</name>
      <address>
        <city>Lyttleton</city>
        <state>Gauteng</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36 - Midrand Medical Centre, Shop #1, Health Emporium, Cnr Church and Market Street</name>
      <address>
        <city>Midrand</city>
        <state>Gauteng</state>
        <zip>1685</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 39 - Medicross Sophiatown, Cnr Edward and Millar Streets</name>
      <address>
        <city>Sophiatown</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 38 - Perinatal HIV Research Unit, New Nurses Home, Chris Hani Baragwanath Academic Hospital, Chris Hani Road</name>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 37 - Excellentis Clinical Trial Consultants, Suite 201, York Building, 72</name>
      <address>
        <city>York Street</city>
        <state>George</state>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 40 - Newtown Clinical Research Centre, Suite 3, Newgate Centre, 104 Jeppe Street</name>
      <address>
        <city>Newtown</city>
        <state>Johannesburg</state>
        <zip>2113</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 46 - Helderberg Clinical Trials Centre, Suite 7G&amp;H Arun Place</name>
      <address>
        <city>Sir Lowry's Pass Road</city>
        <state>Somerset West</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53 - Clinical Trials Unit, Office for Research and Development, His Majesty the King's 80th Birthday December 2007 Building, 3rd floor, room 307, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Rd.</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52 - 1. Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Rama 4 Rd., Pathumwan</city>
        <state>Bangkok</state>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52 - 2. Queen Saovabha Memorial Institute</name>
      <address>
        <city>Thai Red Cross Society, Rama 4 Rd., Pathumwan</city>
        <state>Bangkok</state>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 51 - Faculty of Medicine, Srinakharinwirot University, HRH Princess, Sirindhorn Medical Center</name>
      <address>
        <city>Ongkarak, Nakhorn</city>
        <state>Nayok</state>
        <zip>26120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2013</study_first_posted>
  <results_first_submitted>August 26, 2014</results_first_submitted>
  <results_first_submitted_qc>September 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2014</results_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trivalent inactivated subunit influenza vaccines</keyword>
  <keyword>50 years and above</keyword>
  <keyword>healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 24 sites with 3 sites in Thailand, 4 sites in Philippines, 15 sites in South Africa and 2 sites in Czech Republic.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Agriflu</title>
          <description>Subjects ≥50 years of age who received one vaccination of an investigational vaccine TIV</description>
        </group>
        <group group_id="P2">
          <title>Fluvirin</title>
          <description>Subjects ≥50 years of age who received one vaccination of a control vaccine TIVf</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1452"/>
                <participants group_id="P2" count="1450"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1450"/>
                <participants group_id="P2" count="1440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Eligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Agriflu</title>
          <description>Subjects ≥50 years of age who received one vaccination of an investigational vaccine TIV</description>
        </group>
        <group group_id="B2">
          <title>Fluvirin</title>
          <description>Subjects ≥50 years of age who received one vaccination of a control vaccine TIVf</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1452"/>
            <count group_id="B2" value="1450"/>
            <count group_id="B3" value="2902"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="8.9"/>
                    <measurement group_id="B2" value="64.2" spread="8.9"/>
                    <measurement group_id="B3" value="64.2" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="943"/>
                    <measurement group_id="B2" value="893"/>
                    <measurement group_id="B3" value="1836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="509"/>
                    <measurement group_id="B2" value="557"/>
                    <measurement group_id="B3" value="1066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV Group and TIVf Group for All Three Strains, in Healthy Adults Aged ≥50 Years</title>
        <description>Non-inferiority of Postvaccination Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV (Trivalent Subunit Inactivated Influenza Vaccine) Group Over the Corresponding TIVf Group for All Three Strains, three weeks after vaccination (day 22).
The upper limit of the two-sided 95% confidence interval (CI) on the ratio of GMTs (GMT TIVf/GMT TIV) should not exceed the non-inferiority margin of 1.5.</description>
        <time_frame>Day 22</time_frame>
        <population>Analysis was done on the per-protocol set 1 (PPS1) , ie, the subjects who received the vaccine correctly; provided evaluable serum samples at visit 2; and had no major protocol violations as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Agriflu</title>
            <description>Subjects ≥50 years of age who received one vaccination of an investigational vaccine TIV</description>
          </group>
          <group group_id="O2">
            <title>Fluvirin</title>
            <description>Subjects ≥50 years of age who received one vaccination of a control vaccine TIVf</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV Group and TIVf Group for All Three Strains, in Healthy Adults Aged ≥50 Years</title>
          <description>Non-inferiority of Postvaccination Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs) of TIV (Trivalent Subunit Inactivated Influenza Vaccine) Group Over the Corresponding TIVf Group for All Three Strains, three weeks after vaccination (day 22).
The upper limit of the two-sided 95% confidence interval (CI) on the ratio of GMTs (GMT TIVf/GMT TIV) should not exceed the non-inferiority margin of 1.5.</description>
          <population>Analysis was done on the per-protocol set 1 (PPS1) , ie, the subjects who received the vaccine correctly; provided evaluable serum samples at visit 2; and had no major protocol violations as defined prior to analysis.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1402"/>
                <count group_id="O2" value="1397"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1(1401, 1397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315" lower_limit="281" upper_limit="352"/>
                    <measurement group_id="O2" value="581" lower_limit="519" upper_limit="651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2(1401, 1397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="697" lower_limit="635" upper_limit="764"/>
                    <measurement group_id="O2" value="1048" lower_limit="955" upper_limit="1149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="33" upper_limit="39"/>
                    <measurement group_id="O2" value="36" lower_limit="33" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of HI GMTs of TIV vaccine over HI GMTs of TIVf vaccine for the strain A/H1N1 at day 22</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The HI GMTs of TIV vaccine for strain A/H1N1 considered non-inferior to HI GMTs of TIVf vaccine if the upper limit of the two-sided 95% CI on the ratio of GMTs (GMT TIVf / GMT TIV) was ≤1.5</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.66</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of HI GMTs of TIV vaccine over HI GMTs of TIVf vaccine for the strain A/H3N2 at day 22</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The HI GMTs of TIV vaccine for strain A/H3N2 considered non-inferior to HI GMTs of TIVf vaccine if the upper limit of the two-sided 95% CI on the ratio of GMTs (GMT TIVf / GMT TIV) was ≤1.5</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of HI GMTs of TIV vaccine over HI GMTs of TIVf vaccine for the strain B at day 22</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The HI GMTs of TIV vaccine for strain B considered non-inferior to HI GMTs of TIVf vaccine if the upper limit of the two-sided 95% CI on the ratio of GMTs (GMT TIVf / GMT TIV) was ≤1.5</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects Achieving Seroconversion (SC) in Antibody Titers in the TIV Group Compared With the Corresponding Percentages of Subjects in the TIVf Group for All Three Strains At Day 22, in Healthy Adults Aged ≥50 Years</title>
        <description>Non-Inferiority was measured as the percentages of subjects who achieved seroconversion in HI titers three weeks (day 22) after vaccination of TIV compared with TIVf, against each of three vaccine strains.
Seroconversion is defined as a prevaccination titer &lt;10 and postvaccination HI ≥40 or as a prevaccination titer ≥10 and at minimum four-fold rise in postvaccination antibody titer.
The upper limit of the two-sided 95% CI on the difference between the seroconversion rates (Seroconversion TIVf - SeroconversionTIV) should not exceed 10%.</description>
        <time_frame>Day 22</time_frame>
        <population>Analysis was done on the PPS2, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at visit 1 and visit 2; and had no major protocol violations as defined prior to analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Agriflu</title>
            <description>Subjects ≥50 years of age who received one vaccination of an investigational vaccine TIV</description>
          </group>
          <group group_id="O2">
            <title>Fluvirin</title>
            <description>Subjects ≥50 years of age who received one vaccination of a control vaccine TIVf</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Achieving Seroconversion (SC) in Antibody Titers in the TIV Group Compared With the Corresponding Percentages of Subjects in the TIVf Group for All Three Strains At Day 22, in Healthy Adults Aged ≥50 Years</title>
          <description>Non-Inferiority was measured as the percentages of subjects who achieved seroconversion in HI titers three weeks (day 22) after vaccination of TIV compared with TIVf, against each of three vaccine strains.
Seroconversion is defined as a prevaccination titer &lt;10 and postvaccination HI ≥40 or as a prevaccination titer ≥10 and at minimum four-fold rise in postvaccination antibody titer.
The upper limit of the two-sided 95% CI on the difference between the seroconversion rates (Seroconversion TIVf - SeroconversionTIV) should not exceed 10%.</description>
          <population>Analysis was done on the PPS2, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at visit 1 and visit 2; and had no major protocol violations as defined prior to analysis</population>
          <units>percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1399"/>
                <count group_id="O2" value="1391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1(1397,1391)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="73" upper_limit="78"/>
                    <measurement group_id="O2" value="84" lower_limit="82" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2(1398,1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="70" upper_limit="74"/>
                    <measurement group_id="O2" value="85" lower_limit="83" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B(1399,1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="39" upper_limit="44"/>
                    <measurement group_id="O2" value="40" lower_limit="37" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of percentage of subjects with HI seroconversion of TIV vaccine over TIVf vaccine for the strain A/H1N1 at day 22</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Percentage of subjects with HI seroconversion of TIV vaccine for strain A/H1N1 considered non-inferior to percentage of subjects with HI seroconversion of TIVf vaccine if the upper limit of the two-sided 95% CI on the difference between the seroconversion rates (Seroconversion TIVf – Seroconversion TIV) was ≤10%.</non_inferiority_desc>
            <param_type>Difference in seroconversion rates</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.6</ci_lower_limit>
            <ci_upper_limit>11.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of percentage of subjects with HI seroconversion of TIV vaccine over TIVf vaccine for the strain A/H3N2 at day 22</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Percentage of subjects with HI seroconversion of TIV vaccine for strain A/H3N2 considered non-inferior to percentage of subjects with HI seroconversion of TIVf vaccine if the upper limit of the two-sided 95% CI on the difference between the seroconversion rates (Seroconversion TIVf – Seroconversion TIV) was ≤10%.</non_inferiority_desc>
            <param_type>Difference in seroconversion rates</param_type>
            <param_value>13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.1</ci_lower_limit>
            <ci_upper_limit>16.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of percentage of subjects with HI seroconversion of TIV vaccine over TIVf vaccine for the strain B at day 22</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Percentage of subjects with HI seroconversion of TIV vaccine for strain B considered non-inferior to percentage of subjects with HI seroconversion of TIVf vaccine if the upper limit of the two-sided 95% CI on the difference between the seroconversion rates (Seroconversion TIVf – Seroconversion TIV) was ≤10%.</non_inferiority_desc>
            <param_type>Difference in seroconversion rates</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Percentages of Subjects Who Achieved HI Seroconversion and HI Titer ≥1:40 Against Each of Three Strains After One Vaccination of TIV and TIVf Vaccine</title>
        <description>Percentage of subjects achieving HI seroconversion against each of three vaccine strains was measured three weeks after vaccination of TIV and TIVf vaccine (day 22).
Percentage of subjects who achieved HI titer ≥1:40 against each of three vaccine strains was measured three weeks after one vaccination of TIV and TIVf vaccine.
According to Center for Biologics Evaluation and Research recommendations (CBER 2007), the criterion for seroconversion is considered met if the lower limit of the two-sided 95% CI for the percentage of subjects with HI seroconversion is ≥40% (&lt;65 years) or ≥30% (≥65 years).
As per the CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects who achieved HI titer ≥ 1:40 should be ≥70% (&lt;65 years) or ≥60% (≥65 years).</description>
        <time_frame>Day 22</time_frame>
        <population>Analysis was done on the PPS1 for HI Titer ≥1:40 at day 22 and PPS2 for Seroconversion</population>
        <group_list>
          <group group_id="O1">
            <title>≥50 to ≤64 years_Agriflu</title>
            <description>Subjects ≥50 to ≤64 years of age who received an investigational vaccine TIV</description>
          </group>
          <group group_id="O2">
            <title>≥50 to ≤64 years_Fluvirin</title>
            <description>Subjects ≥50 to ≤64 years of age who received a control vaccine TIVf</description>
          </group>
          <group group_id="O3">
            <title>≥65 years_Agriflu</title>
            <description>Subjects ≥65 years of age who received an investigational vaccine TIV</description>
          </group>
          <group group_id="O4">
            <title>≥65 years_Fluvirin</title>
            <description>Subjects ≥65 years of age who received a control vaccine TIVf</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Percentages of Subjects Who Achieved HI Seroconversion and HI Titer ≥1:40 Against Each of Three Strains After One Vaccination of TIV and TIVf Vaccine</title>
          <description>Percentage of subjects achieving HI seroconversion against each of three vaccine strains was measured three weeks after vaccination of TIV and TIVf vaccine (day 22).
Percentage of subjects who achieved HI titer ≥1:40 against each of three vaccine strains was measured three weeks after one vaccination of TIV and TIVf vaccine.
According to Center for Biologics Evaluation and Research recommendations (CBER 2007), the criterion for seroconversion is considered met if the lower limit of the two-sided 95% CI for the percentage of subjects with HI seroconversion is ≥40% (&lt;65 years) or ≥30% (≥65 years).
As per the CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects who achieved HI titer ≥ 1:40 should be ≥70% (&lt;65 years) or ≥60% (≥65 years).</description>
          <population>Analysis was done on the PPS1 for HI Titer ≥1:40 at day 22 and PPS2 for Seroconversion</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="691"/>
                <count group_id="O2" value="691"/>
                <count group_id="O3" value="711"/>
                <count group_id="O4" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 – Seroconversion(687, 686, 710, 705)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="74" upper_limit="81"/>
                    <measurement group_id="O2" value="87" lower_limit="84" upper_limit="89"/>
                    <measurement group_id="O3" value="73" lower_limit="70" upper_limit="77"/>
                    <measurement group_id="O4" value="81" lower_limit="78" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 – Seroconversion(688, 686, 710, 704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="75" upper_limit="81"/>
                    <measurement group_id="O2" value="88" lower_limit="85" upper_limit="90"/>
                    <measurement group_id="O3" value="66" lower_limit="63" upper_limit="70"/>
                    <measurement group_id="O4" value="82" lower_limit="79" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B – Seroconversion(688, 686, 711, 704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="40" upper_limit="48"/>
                    <measurement group_id="O2" value="45" lower_limit="41" upper_limit="49"/>
                    <measurement group_id="O3" value="39" lower_limit="35" upper_limit="42"/>
                    <measurement group_id="O4" value="35" lower_limit="32" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 – HI ≥1:40 (Day 22)[691, 691, 710, 706]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="92" upper_limit="96"/>
                    <measurement group_id="O2" value="96" lower_limit="94" upper_limit="97"/>
                    <measurement group_id="O3" value="91" lower_limit="89" upper_limit="93"/>
                    <measurement group_id="O4" value="92" lower_limit="90" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 – HI ≥1:40 (Day 22)[691, 691, 710, 706]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="98" upper_limit="99"/>
                    <measurement group_id="O4" value="98" lower_limit="97" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B – HI ≥1:40 (Day 22)[691, 691, 711, 706]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="55" upper_limit="62"/>
                    <measurement group_id="O2" value="59" lower_limit="55" upper_limit="63"/>
                    <measurement group_id="O3" value="59" lower_limit="55" upper_limit="62"/>
                    <measurement group_id="O4" value="56" lower_limit="52" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio of Subjects Against Each of Three Strains After One Vaccination of TIV and TIVf Vaccine</title>
        <description>Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs against each of three vaccine strains, three weeks after vaccination of TIV and TIVf vaccine (day 22).</description>
        <time_frame>Day 22</time_frame>
        <population>Analysis was done on the PPS1</population>
        <group_list>
          <group group_id="O1">
            <title>≥50 to ≤64 years_Agriflu</title>
            <description>Subjects ≥50 to ≤64 years of age who received an investigational vaccine TIV</description>
          </group>
          <group group_id="O2">
            <title>≥50 to ≤64 years_Fluvirin</title>
            <description>Subjects ≥50 to ≤64 years of age who received a control vaccine TIVf</description>
          </group>
          <group group_id="O3">
            <title>≥65 years_Agriflu</title>
            <description>Subjects ≥65 years of age who received an investigational vaccine TIV</description>
          </group>
          <group group_id="O4">
            <title>≥65 years_Fluvirin</title>
            <description>Subjects ≥65 years of age who received a control vaccine TIVf</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio of Subjects Against Each of Three Strains After One Vaccination of TIV and TIVf Vaccine</title>
          <description>Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs against each of three vaccine strains, three weeks after vaccination of TIV and TIVf vaccine (day 22).</description>
          <population>Analysis was done on the PPS1</population>
          <units>Ratios</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="688"/>
                <count group_id="O2" value="686"/>
                <count group_id="O3" value="711"/>
                <count group_id="O4" value="705"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1(687, 686, 710, 705)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O2" value="35" lower_limit="29" upper_limit="42"/>
                    <measurement group_id="O3" value="15" lower_limit="12" upper_limit="19"/>
                    <measurement group_id="O4" value="27" lower_limit="21" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2(688, 686, 710, 704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O2" value="18" lower_limit="15" upper_limit="20"/>
                    <measurement group_id="O3" value="9.65" lower_limit="7.94" upper_limit="12"/>
                    <measurement group_id="O4" value="16" lower_limit="13" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B(688, 686, 711, 704)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" lower_limit="3.43" upper_limit="4.31"/>
                    <measurement group_id="O2" value="3.91" lower_limit="3.49" upper_limit="4.39"/>
                    <measurement group_id="O3" value="3.1" lower_limit="2.71" upper_limit="3.54"/>
                    <measurement group_id="O4" value="3" lower_limit="2.62" upper_limit="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Solicited Local and Systemic Adverse Events After One Vaccination of TIV and TIVf</title>
        <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after vaccination of TIV and control.</description>
        <time_frame>Day 1 to 7 postvaccination</time_frame>
        <population>Analysis was done on the safety dataset, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Agriflu</title>
            <description>Subjects ≥50 years of age who received one vaccination of an investigational vaccine TIV</description>
          </group>
          <group group_id="O2">
            <title>Fluvirin</title>
            <description>Subjects ≥50 years of age who received one vaccination of a control vaccine TIVf</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Solicited Local and Systemic Adverse Events After One Vaccination of TIV and TIVf</title>
          <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events from day 1 up to and including day 7 after vaccination of TIV and control.</description>
          <population>Analysis was done on the safety dataset, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1428"/>
                <count group_id="O2" value="1433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain(1412, 1424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis Type I(1419, 1425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis Type II(1419, 1425)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Type I(1410, 1427)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Type II(1410, 1427)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration Type I(1423, 1429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration Type II(1423, 1429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Type I(1419, 1427)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Type II(1419, 1427)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills(1403,1407)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise(1402,1405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea(1401,1405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia(1400,1403)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia(1396,1403)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache(1397,1403)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating(1403,1405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue(1404,1407)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of Appetite(1404,1403)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever(&gt;=38°C)[1422,1428]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 22 days</time_frame>
      <desc>Adverse events and Serious Adverse Events were collected from day 1 through day 22.
The number of subjects analyzed in this section is from the safety set. Safety Set (Overall) includes all subjects in the exposed set who had either postvaccination AE or solicited AE data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Agriflu</title>
          <description>Subjects ≥50 years of age who received one vaccination of an investigational vaccine TIV</description>
        </group>
        <group group_id="E2">
          <title>Fluvirin</title>
          <description>Subjects ≥50 years of age who received one vaccination of a control vaccine TIVf</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>Total number of Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2897"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2897"/>
              </event>
              <event>
                <sub_title>JAUNDICE CHOLESTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BASAL GANGLIA HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2897"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="471" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="467" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="938" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="290" subjects_at_risk="2897"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="281" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="276" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="557" subjects_at_risk="2897"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="184" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="173" subjects_at_risk="2897"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="274" subjects_at_risk="2897"/>
              </event>
              <event>
                <sub_title>Headach</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="323" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="1452"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="1445"/>
                <counts group_id="E3" subjects_affected="202" subjects_at_risk="2897"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

